Technology Holding, LLC — Department of Defense SBIR Phase II: DHA202-003
Technology Holding, LLC — SBIR Phase II award from Department of Defense.
- Amount
- $1,099,026
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase II
- Topic
- DHA202-003
- Solicitation
- 20.2
- NAICS
- —
- Place of performance
- UT
- Period
- 2023-02-22 → 2023-07-26
Description
Antibiotic resistant infections are a principal concern for the Department of Defense and society at large due to the current lack of available treatments. Monoclonal antibodies represent a promising drug class that could be applied to antibiotic resistant infections to harness a patients own immune system to effectively combat the invading threat. In this program we continue program development to determine binding epitopes of novel antibody candidates, express candidates, and show infectivity reduction potential in in vitro and in vivo assays.